Question: How can test developers check their results?

Answer passage (source: CDC):
page_title: Frequently Asked Questions about Laboratory Testing and COVID-19
section_headers: For All Laboratories: Accessing Laboratory Testing
Can a pooling strategy be used to expand nucleic acid testing for SARS-CoV-2?
section_content: In areas with low COVID-19 prevalence, a two-stage specimen pooling approach
can help preserve testing reagents and resources. In the first stage, several
patients’ specimens are combined before extraction, and then tested all at
once. If the test comes back negative, then all of those patients can be
cleared with one test. If the test comes back positive, then all of those
specimens need to be extracted and re-tested individually.
The lower the prevalence of the disease, the larger the optimal pool size can
be. A recent studyexternal
icon from the
Nebraska Public Health Laboratory found that polymerase chain reaction (PCR)
tests for SARS-CoV-2 reliably return a positive result when one positive
sample is mixed with four negatives. Researchers in Germany and Israel have
had similar results.
A pooling strategy is not efficient when the prevalence of COVID-19 is
high. People with symptoms and people who have been exposed to someone with a
confirmed SARS-CoV-2 infection should still be tested individually.
Before using a pooling strategy, the laboratory must have the proper
regulatory approvals. If the manufacturer’s guidelines and the emergency use
authorization (EUA) for that SARS-CoV-2 test do not stipulate pooling,
laboratories that use authorized nucleic acid devices can still bridge to
alternative components, including extraction methods, PCR instruments,
software versions, etc., under Section IV. A. 4. of FDA’s Policy for COVID-19
Tests During the Public Health Emergencyexternal
icon. These component changes can be achieved through evaluation
and verification of the performance of the component with the test, without a
new EUA or an amendment to the original EUA. Additional detail and suggested
studies are discussed in FDA’s policy. The process used for such changes must
also comply with Clinical Laboratory Improvement Amendments
(CLIA) guidelines.

Reviewer feedback on this answer:
Gives no information on how to check results for kit developers
Seems like a pretty decent answer. The bulk of the response doesn't directly address the question but seems to get around to it at the end. There's also relevant links that are helpful for the question

Reviewer ratings:
Bad
Acceptable

Answer passage (source: CDC):
page_title: Test for Current Infection
section_headers: What to do after a viral test
section_content: To get your test result, please check with the group that performed your test,
such as your healthcare provider or your health department. Check the CDC
website to locate your health department
information.
How long it will take to get your test results back depends on the test used.

If you test positive for COVID-19, know what protective steps to take If You Are Sick or Caring for Someone.
If you test negative for COVID-19, you probably were not infected at the time your sample was collected. However, that does not mean you will not get sick. It is possible that you were very early in your infection when your sample was collected and that you could test positive later. Or you could be exposed later and then develop illness. In other words, a negative test result does not mean you won’t get sick later. This means you could still spread the virus.


Reviewer feedback on this answer:
This is for consumers of the test not developers.
This is talking about the test results of people who take the tests, not results from test developers which is what the question is asking about. Misses the mark

Reviewer ratings:
Bad
Bad

Answer passage (source: CDC):
page_title: Frequently Asked Questions about Laboratory Testing and COVID-19
section_headers: For All Laboratories: Test Developers
Where do test developers get the genomic RNA needed to validate test performance for FDA?
section_content: 
Currently, genomic RNA material can be used for validation purposes in biosafety level 2 laboratories (BSL-2). Genomic RNA material is available through BEI Resourcesexternal icon. Registrationexternal icon with BEI Resources is required to request SARS-CoV-2 materials. BEI Resources is prioritizing and fast-tracking all SARS-CoV-2 registrations with a 12- to 72-hour turnaround time for all SARS-CoV-2-related registrations. Please contact BEI Resources at contact@beiresources.org or 1-800 359-7370 for questions.
Developers are required to sign a material transfer agreement prior to the release of materials.
All BEI Resources reagents are provided worldwide. There is no cost for the reagents themselves. However, shipping and handling charges may apply.
Commercial sources also may have this material.
For Public Health Laboratories: If a kit to detect the virus (SAR-CoV-2) is needed, contact the International Reagent Resource external icon


Reviewer feedback on this answer:
This answer seems to respond to the question exactly as expected. There's a lot of information as well as external links and contact information for further questions. This covers it all
This speaks to the material for the kits only

Reviewer ratings:
Excellent
Bad